Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibandronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 19/20 | 0.97 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.97 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.97 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibandronic Acid SCHEMBL3419518 | 1.00 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1240197 | 0.98 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL365290 | 0.98 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL28564280 | 0.98 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3415425 | 0.98 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL9183 | 0.98 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL5818379 | 0.98 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3630021 | 0.97 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3624745 | 0.97 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3628878 | 0.97 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110063939-B | Hollow hydroxyapatite drug-loaded particle for shock wave mediated release and preparation method thereof | 邢更彦 | 2021-08-17 | — | — | CN | claimed |
| CN-112891621-A | Artificial bone material carrying anti-osteoporosis medicine and method for preparing artificial bone | 中南大学湘雅医院 | 2021-06-04 | — | — | CN | claimed |
| CN-109999220-A | The preparation method of fiber reinforced calcium orthophosphate base bone renovating material for 3D printing | 西南交通大学 | 2019-07-12 | — | — | CN | claimed |
| CN-106511356-B | A kind of ibandronic acid composition of sodium and preparation method thereof | 南京恒生制药有限公司 | 2019-02-26 | — | — | CN | claimed |
| CN-106006593-B | A kind of nano-calcium phosphate preparation method of simple and effective | 西南交通大学 | 2018-08-17 | — | — | CN | claimed |
| CN-106511356-A | Sodium ibandronate composition and preparation method thereof | 南京恒生制药有限公司 | 2017-03-22 | — | — | CN | claimed |
| CN-106006593-A | Simple and efficient preparation method of nano calcium phosphate | 西南交通大学 | 2016-10-12 | — | — | CN | claimed |
| CN-103182099-B | Porous active artificial bone and preparation method thereof | SHENZHEN LANDO BIOMATERIALS CO LTD | 2015-02-18 | — | — | CN | claimed |
| EP-1880744-B1 | Bisphosphonic acids for the treatment and prevention of osteoporosis | HOFFMANN LA ROCHE (CH) | 2015-01-21 | — | — | EP | claimed |
| CN-102645513-B | Method for determining sodion content in diphosphonic acid monosodium salt compound | CHENGDU EASTON PHARMACEUTICAL | 2014-07-16 | — | — | CN | claimed |
| CN-101279985-B | Synthetic method of ibandronate | SUZHOU HANDEPHARM TECHNOLOGY CO LTD | 2012-09-05 | — | — | CN | claimed |
| CN-102645513-A | Method for determining sodion content in diphosphonic acid monosodium salt compound | CHENGDU EASTON PHARMACEUTICAL | 2012-08-22 | — | — | CN | claimed |
| EP-1716161-B1 | Ibandronic acid monosodium salt in the amorphous form | ALCHYMARS S P A (IT) | 2011-05-04 | — | — | EP | claimed |
| US-7723542-B2 | Process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof | TRIFARMA S.P.A. (IT) | 2010-05-25 | — | — | US | claimed |
| CN-101279985-A | Synthetic method of ibandronate | SHENZHEN HANDEPHARM TECHNOLOGY (CN) | 2008-10-08 | — | — | CN | claimed |
| CN-101117339-A | Method for preparing sodium ibandronate crystal and hydrated crystal thereof | CHONGQING SHENGHUAXI PHARMA CO (CN) | 2008-02-06 | — | — | CN | claimed |
| CN-101022812-A | Solid and crystalline ibandronate sodium and processes for preparation thereof | TEVA PHARMA (IL) | 2007-08-22 | — | — | CN | claimed |
| US-20070112197-A1 | Process for the preparation of alkyl-and aryl-diphosphonic acids and salts thereof | TRIFARMA S.P.A. (IT) | 2007-05-17 | — | — | US | claimed |
| EP-1716161-A2 | A PROCESS FOR THE PREPARATION OF ALKYL- AND ARYL-DIPHOSPHONIC ACIDS AND SALTS THEREOF | Lyogen Limited (CY) | 2006-11-02 | — | — | EP | claimed |
| WO-2005063779-A2 | A PROCESS FOR THE PREPARATION OF ALKYL- AND ARYL-DIPHOSPHONIC ACIDS AND SALTS THEREOF | LYOGEN LIMITED (CY) | 2005-07-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112197-A1 | Process for the preparation of alkyl-and aryl-diphosphonic acids and salts thereof | BPGM, P2RY6, P2RY12 | FDPS 58/4885GGPS1 278/4885AGTR1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.